nasdaq aemd is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer . to augment the body s natural immune defenses the aethlon hemopurifier eliminates life threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies . the technology captures circulating viruses bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection . at present the hemopurifier is being advanced under an fda approved clinical study . aethlon is also the majority owner of exosome sciences inc. a company focused on the discovery of exosomal biomarkers to diagnose and monitor life threatening diseases . back to top news 10.13.16 aethlon medical achieves darpa milestones including middle east respiratory syndrome coronavirus mers cov validation 10.12.16 aethlon medical announces corporate update presentation at next week s 2016 bio investor forum events 10.18.16 10.18.16 bio investor forum back to top site main navigation the hemopurifier the hemopurifier in infectious disease the hemopurifier in cancer about aethlon corporate profile exosome sciences inc. executive team board of directors scientific advisory board news coverage contact us investor relations events & presentations news releases interactive charts corporate governance sec filings faqs email alerts careers back to top site tertiary navigation register for updates contact site map search the site back to top site footer navigation the hemopurifier about aethlon investor relations careers terms of use privacy policy copyright 2016 aethlon medical . all rights reserved . back to top